Table 1.
Clinical Characteristics of Chronic Hepatitis B Patients, LC Patients, and Healthy Controls
| Group | CHB | LC | Healthy controls |
|---|---|---|---|
| Case number (male/female) | 54 (33/21) | 31 (17/14) | 11 (6/5) |
| Age (years) | 40.69±11.86a | 49.87±12.58b | 38.43±12.89 |
| HBeAg(+)/HBeAg(−) | 24/30 | 10/21 | NA |
| ALT (U/L) | 162.61±140.16a,b | 74.35±89.50b | 22.27±7.40 |
| AST (U/L) | 101.11±128.78b | 78.58±64.38b | 20.91±5.84 |
| GGT (U/L) | 141.55±99.79a,b | 88.71±69.64b | 18.67±13.53 |
| AKP (U/L) | 110.55±51.91b | 130.94±63.74b | 69.56±23.56 |
| TBIL (μM) | 42.29±43.29b | 47.71±45.18b | 7.73±3.49 |
| HBV-DNA (log10 copies/mL) | 4.13±1.51 | 4±1.04 | NA |
| ALB (g/L) | 40.85±5.61a,b | 32.74±5.02b | 46.42±2.71 |
| BUN (mM) | 4.98±4.21 | 5.07±1.63 | 4.86±1.97 |
| Cr (μM) | 69.61±18.74 | 62.76±10.92 | 67.89±14.71 |
| Na (mM) | 142.51±3.27a | 138.35±6.35 | 140.39±5.43 |
| PT (s) | 11.42±1.63a | 13.74±2.39b | 10.40±1.59 |
| PTA (%) | 92.95±18.17a | 72.97±19.17b | 97.28±18.57 |
| PT-INR | 1.03±0.12a | 1.20±0.17 | 1.06±0.14 |
| APTT (s) | 32.37±2.86 | 33.82±7.06 | 33.21±3.96 |
| Ascites (N) | 0 | 26 (83.87%) | NA |
| Variceal bleeding (N) | 0 | 2 (6.45%) | NA |
| Hepatic encephalopathy (N) | 0 | 4 (12.90%) | NA |
| Grade 1 | 1 (3.22%) | ||
| Grade 2 | 3 (9.68%) | ||
| Grade 3 | 0 | ||
| Grade 4 | 0 | ||
| Jaundices (N) | 0 | 16 (51.61%) | NA |
a
P<0.05, CHB patients compared with LC patients.
b
P<0.05, patient group compared with healthy controls.
CHB, chronic hepatitis B; LC, liver cirrhosis; HC, healthy controls; NA, not available; N, number of patients; HBV, hepatitis B virus; ALT and AST, aminotransferases; GGT, γ-glutamyl transpeptidase; AKP, alkaline phosphatase; TBIL, total bilirubin; BUN, blood urea nitrogen; Cr, creatine; PT, prothrombin time; PTA, prothrombin activity; PT-INR, prothrombin-international normalized ratio; APTT, activated partial thromboplastin time.